Sanofi Completes Dosing in Phase 1 Trial of 'Dupixent' Utilizing Alteogen's Technology
Sanofi's 'Dupixent' (ingredient: dupilumab), which utilizes Alteogen's subcutaneous (SC) injection platform technology, has completed dosing for participants in its phase 1 clinical trial.
Exterior view of Alteogen headquarters and research center in Yuseong-gu, Daejeon. Alteogen
View original imageAccording to the clinical information site ClinicalTrials on July 23, Sanofi plans to complete its phase 1 clinical trial of Dupixent, administered in combination with Alteogen's hyaluronidase 'ALT-B4' (ingredient: verahyaluronidase alpha), by September.
This phase 1 trial, which began in June, was conducted on 40 healthy adult participants. The purpose of the trial is to evaluate the pharmacokinetics (PK), safety, and anti-drug antibodies (ADA) following the co-administration of Dupixent and ALT-B4.
Hot Picks Today
Unemployment Benefits to Drop from 1.98 Million to 1.76 Million Won per Month...Employment Insurance Premium Rate to Rise from 1.8% to 2%
- "Should Get at Least 45 Million Won Salary" "Can't Give Up on Large Companies"... Young People Say There Are No Places to Apply
- ELS and Governance Reform Stalled for Over Half a Year to Be Resolved in September
- “A Dol Ring Received at 200,000 Won Is Now Worth 800,000 Won... Should I Give the Same in Return?”
- When "Cutting Down Reserved Tents" Brings Relief: Local Governments Take Action Against Escalating 'Reserved Tent' Problem
The ALT-B4 used in this trial is a recombinant human hyaluronidase enzyme developed by Alteogen, enabling the subcutaneous injection of large-volume drugs and facilitating their absorption in the body. Sanofi is utilizing Alteogen's technology to develop a new formulation of Dupixent aimed at improving dosing convenience.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
